StockNews.com Downgrades ProQR Therapeutics (NASDAQ:PRQR) to Sell

ProQR Therapeutics (NASDAQ:PRQRGet Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Wednesday.

PRQR has been the subject of a number of other reports. Chardan Capital reissued a “buy” rating and issued a $2.50 price target on shares of ProQR Therapeutics in a research report on Friday, May 10th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of ProQR Therapeutics in a research report on Friday, May 10th. Finally, Citigroup boosted their price target on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, ProQR Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $3.38.

View Our Latest Report on PRQR

ProQR Therapeutics Trading Down 1.0 %

ProQR Therapeutics stock opened at $1.99 on Wednesday. ProQR Therapeutics has a 12-month low of $1.11 and a 12-month high of $3.29. The stock has a market cap of $161.91 million, a P/E ratio of -5.38 and a beta of 0.35. The company has a fifty day simple moving average of $2.01 and a 200-day simple moving average of $2.03.

ProQR Therapeutics (NASDAQ:PRQRGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. ProQR Therapeutics had a negative net margin of 260.75% and a negative return on equity of 61.58%. The firm had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $3.31 million. As a group, sell-side analysts forecast that ProQR Therapeutics will post -0.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ikarian Capital LLC raised its holdings in shares of ProQR Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after buying an additional 10,958 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of ProQR Therapeutics by 120.1% during the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 19,100 shares during the period. RFG Advisory LLC acquired a new position in shares of ProQR Therapeutics during the first quarter worth about $73,000. Acadian Asset Management LLC acquired a new position in shares of ProQR Therapeutics during the first quarter worth about $56,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of ProQR Therapeutics during the first quarter worth about $26,000. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

(Get Free Report)

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

Recommended Stories

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.